Nexien Biopharma (OTCMKTS:NXEN – Get Free Report) and Cytokinetics (NASDAQ:CYTK – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings and risk.
Valuation and Earnings
This table compares Nexien Biopharma and Cytokinetics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nexien Biopharma | N/A | N/A | -$240,000.00 | N/A | N/A |
| Cytokinetics | $88.04 million | 108.49 | -$784.96 million | ($6.84) | -11.22 |
Analyst Recommendations
This is a summary of recent ratings and price targets for Nexien Biopharma and Cytokinetics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nexien Biopharma | 0 | 0 | 0 | 0 | 0.00 |
| Cytokinetics | 1 | 1 | 18 | 1 | 2.90 |
Cytokinetics has a consensus price target of $100.85, indicating a potential upside of 31.38%. Given Cytokinetics’ stronger consensus rating and higher probable upside, analysts plainly believe Cytokinetics is more favorable than Nexien Biopharma.
Profitability
This table compares Nexien Biopharma and Cytokinetics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nexien Biopharma | N/A | N/A | N/A |
| Cytokinetics | -1,321.12% | N/A | -56.07% |
Risk & Volatility
Nexien Biopharma has a beta of -0.91, meaning that its share price is 191% less volatile than the S&P 500. Comparatively, Cytokinetics has a beta of 0.38, meaning that its share price is 62% less volatile than the S&P 500.
Summary
Cytokinetics beats Nexien Biopharma on 6 of the 9 factors compared between the two stocks.
About Nexien Biopharma
Nexien BioPharma, Inc. focuses on the formulation, development, and commercialization of cannabinoid-based pharmaceuticals, drug delivery systems, and related technologies for diseases, disorders, and medical conditions. The company was formerly known as Intiva BioPharma Inc. and changed its name to Nexien BioPharma, Inc. in September 2018. Nexien BioPharma, Inc. is based in Glendale, Colorado.
About Cytokinetics
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
Receive News & Ratings for Nexien Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nexien Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
